Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine

被引:32
作者
Hirano, Toshihiko [1 ]
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Clin Pharmacol, Hachioji, Tokyo 1920392, Japan
关键词
cellular pharmacodynamics; immunosuppressive drug; organ transplantation; immunological disorders; individualized medicine;
D O I
10.1016/j.intimp.2006.09.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The therapeutic effects of immunosuppressive drugs are known to deviate largely between patients, but efficient strategies for the differentiation of patients who show clinical resistance to immunosuppressive therapies have not been established. Accordingly, a considerable number of patients receive treatment with immuno suppressive drugs despite the onset of serious side effects and poor responses. Cellular pharmacodynamics of immunosuppressive drugs in vitro using peripheral lymphocytes derived from each patient, an attractive way to distinguish resistant patients, is respected and has been applied to the carrying out of individualized immunosuppressive therapy. In this article, I summarize experimental procedures for assaying immune cell responses to immunosuppressive drugs in vitro, and highlight the relationship between cellular sensitivity to immunosuppressive drugs and the therapeutic efficacy of drugs in organ transplantation and several immunological disorders. I will also overview the molecular mechanisms and genetic bases for cellular and clinical resistance to immuno suppressive drugs. Lastly, the future clinical prospects for the application of in vitro drug sensitivity tests for "patient-tailored" immunosuppressive therapies are discussed. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 22
页数:20
相关论文
共 194 条
  • [51] Immunosuppressive agents in dermatology - An update
    Dutz, JP
    Ho, VC
    [J]. DERMATOLOGIC CLINICS, 1998, 16 (02) : 235 - +
  • [52] Successful treatment of myasthenia gravis with tacrolimus
    Evoli, A
    Di Schino, C
    Marsili, F
    Punzi, C
    [J]. MUSCLE & NERVE, 2002, 25 (01) : 111 - 114
  • [53] High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
    Farrell, RJ
    Murphy, A
    Long, A
    Donnelly, S
    Cherikuri, A
    O'Toole, D
    Mahmud, N
    Keeling, PWN
    Weir, DG
    Kelleher, D
    [J]. GASTROENTEROLOGY, 2000, 118 (02) : 279 - 288
  • [54] Response of refractory colitis to intravenous or oral tacrolimus (FK506)
    Fellermann, K
    Tanko, T
    Herrlinger, KR
    Witthoeft, T
    Homann, N
    Bruening, A
    Ludwig, D
    Stange, EF
    [J]. INFLAMMATORY BOWEL DISEASES, 2002, 8 (05) : 317 - 324
  • [55] CYCLOSPORINE MONITORING IN PSORIASIS
    FEUTREN, G
    FRIEND, D
    TIMONEN, P
    LABURTE, C
    [J]. LANCET, 1990, 335 (8693) : 866 - 867
  • [56] FEUTREN G, 1990, TRANSPLANT P, V22, P1299
  • [57] ADVERSE INFLUENCE OF RECIPIENT LYMPHOID RESISTANCE TO INVITRO IMMUNOSUPPRESSION ON THE OUTCOME OF KIDNEY-TRANSPLANTS
    FRANCIS, DMA
    DUMBLE, LJ
    BOWES, L
    CLUNIE, GJA
    MACDONALD, IM
    [J]. TRANSPLANTATION, 1988, 46 (06) : 853 - 857
  • [58] MINERALOCORTICOID ACTION - TARGET TISSUE-SPECIFICITY IS ENZYME, NOT RECEPTOR, MEDIATED
    FUNDER, JW
    PEARCE, PT
    SMITH, R
    SMITH, AI
    [J]. SCIENCE, 1988, 242 (4878) : 583 - 585
  • [59] Furst DE, 1995, BRIT J RHEUMATOL, V34, P20
  • [60] Persistent activation of nuclear factor-κB signaling pathway in severe uncontrolled asthma
    Gagliardo, R
    Chanez, P
    Mathieu, M
    Bruno, A
    Costanzo, G
    Gougat, C
    Vachier, I
    Bousquet, L
    Bonsignore, G
    Vignola, AM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (10) : 1190 - 1198